Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/10/21
Inovio Pharmaceuticals (INO) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/09/21
INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine CandidatePRNewsWire • 08/09/21
INOVIO Doses First Participant in Phase 2 Trial for its DNA Vaccine Against Middle East Respiratory Syndrome (MERS), a Coronavirus DiseasePRNewsWire • 08/04/21
INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800PRNewsWire • 06/08/21